Junxun Ma

1.2k total citations
45 papers, 796 citations indexed

About

Junxun Ma is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Junxun Ma has authored 45 papers receiving a total of 796 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Junxun Ma's work include Cancer Immunotherapy and Biomarkers (24 papers), Lung Cancer Treatments and Mutations (16 papers) and Lung Cancer Research Studies (8 papers). Junxun Ma is often cited by papers focused on Cancer Immunotherapy and Biomarkers (24 papers), Lung Cancer Treatments and Mutations (16 papers) and Lung Cancer Research Studies (8 papers). Junxun Ma collaborates with scholars based in China, United States and Japan. Junxun Ma's co-authors include Yi Hu, Pengfei Cui, Haitao Tao, Jinliang Wang, Zhefeng Liu, Shixue Chen, Yuanyu Qian, Di Huang, Zhaozhen Wu and Ziwei Huang and has published in prestigious journals such as Journal of Clinical Oncology, Oncogene and Frontiers in Immunology.

In The Last Decade

Junxun Ma

42 papers receiving 793 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Junxun Ma China 18 596 373 135 124 95 45 796
Hayato Kawachi Japan 12 549 0.9× 435 1.2× 88 0.7× 92 0.7× 83 0.9× 35 711
Suchita Pakkala United States 15 685 1.1× 522 1.4× 120 0.9× 154 1.2× 102 1.1× 32 973
Amaury Daste France 13 610 1.0× 279 0.7× 173 1.3× 129 1.0× 167 1.8× 66 848
Zhuoran Yao China 8 660 1.1× 220 0.6× 254 1.9× 133 1.1× 71 0.7× 19 817
Guoqiang Wang China 9 455 0.8× 227 0.6× 101 0.7× 89 0.7× 62 0.7× 24 561
Zhefeng Liu China 14 382 0.6× 235 0.6× 73 0.5× 137 1.1× 57 0.6× 36 615
Audrey Simonaggio France 10 445 0.7× 278 0.7× 82 0.6× 104 0.8× 48 0.5× 23 567
Aliyah Pabani Canada 13 629 1.1× 533 1.4× 82 0.6× 80 0.6× 86 0.9× 32 814
Giulia Mazzaschi Italy 11 444 0.7× 254 0.7× 166 1.2× 130 1.0× 50 0.5× 54 634
Jia Song China 12 387 0.6× 220 0.6× 120 0.9× 113 0.9× 133 1.4× 27 631

Countries citing papers authored by Junxun Ma

Since Specialization
Citations

This map shows the geographic impact of Junxun Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junxun Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junxun Ma more than expected).

Fields of papers citing papers by Junxun Ma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junxun Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junxun Ma. The network helps show where Junxun Ma may publish in the future.

Co-authorship network of co-authors of Junxun Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Junxun Ma. A scholar is included among the top collaborators of Junxun Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junxun Ma. Junxun Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ge, Xiangwei, Hao Fan, Hongyang Yu, et al.. (2024). STING facilitates the development of radiation-induced lung injury via regulating the PERK/eIF2α pathway. Translational Lung Cancer Research. 13(11). 3010–3025. 3 indexed citations
3.
4.
Sun, Binbin, Hong-Jun Hao, Huan Yan, et al.. (2023). Programmed Cell Death Protein 1 Inhibitor-Mediated Peripheral Neuropathy. JTO Clinical and Research Reports. 4(4). 100495–100495. 3 indexed citations
5.
Gao, Ming, Xia Zhang, Huan Yan, et al.. (2023). Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer. Supportive Care in Cancer. 31(12). 671–671. 5 indexed citations
6.
Li, Tao, Yibing Bai, Ming Gao, et al.. (2023). Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China. Frontiers in Oncology. 13. 1147903–1147903. 4 indexed citations
7.
8.
Wu, Zhaozhen, Haitao Tao, Sujie Zhang, et al.. (2021). Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting. Cancer Immunology Immunotherapy. 70(10). 2971–2980. 10 indexed citations
9.
Chen, Shixue, Zhibo Zhang, Xuan Zheng, et al.. (2021). Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. Frontiers in Oncology. 11. 562315–562315. 83 indexed citations
10.
Zhang, Zhibo, Yuan Fang, Runzhe Chen, et al.. (2020). Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors. Frontiers in Immunology. 11. 1173–1173. 33 indexed citations
11.
Chen, Shixue, Ziwei Huang, Wangping Jia, et al.. (2020). <p>Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors</p>. Journal of Hepatocellular Carcinoma. Volume 7. 289–299. 24 indexed citations
12.
Sun, Danyang, Junxun Ma, Jinliang Wang, et al.. (2020). A real-world study of the efficacy and safety of anti-programmed cell death-1 therapy combined with chemotherapy or targeted therapy in patients with advanced biliary tract cancer. Journal of Gastrointestinal Oncology. 11(6). 1421–1430. 3 indexed citations
13.
Ge, Xiangwei, Zhibo Zhang, Sujie Zhang, et al.. (2020). Immunotherapy beyond progression in patients with advanced non-small cell lung cancer. Translational Lung Cancer Research. 9(6). 2391–2400. 27 indexed citations
14.
Sun, Danyang, Junxun Ma, Jinliang Wang, et al.. (2019). Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer. Cancer Immunology Immunotherapy. 68(9). 1527–1535. 39 indexed citations
15.
Cui, Pengfei, Zhefeng Liu, Guoqiang Wang, et al.. (2018). Risk factors for pneumonitis in patients treated with anti‐programmed death‐1 therapy: A case‐control study. Cancer Medicine. 7(8). 4115–4120. 90 indexed citations
16.
Zhuang, Wu, Junxun Ma, Xudong Chen, et al.. (2018). The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel. Journal of Cancer. 9(13). 2302–2307. 20 indexed citations
17.
Cui, Pengfei, Junxun Ma, Feixue Wang, et al.. (2017). Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis. Therapeutics and Clinical Risk Management. Volume 13. 1259–1271. 12 indexed citations
18.
Fu, Yan, Jia Hu, Nan Du, et al.. (2015). Bevacizumab plus chemotherapy versus chemotherapy alone for preventing brain metastasis derived from advanced lung cancer. Journal of Chemotherapy. 28(3). 218–224. 21 indexed citations
19.
Fu, Yan, et al.. (2014). Expression of HSPA2 in human hepatocellular carcinoma and its clinical significance. Tumor Biology. 35(11). 11283–11287. 17 indexed citations
20.
Du, Nan, Xiaosong Li, Fang Li, et al.. (2013). Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion. Oncology Reports. 29(6). 2332–2340. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hayato Kawachi Breakdown of academic impact, for papers by Suchita Pakkala Breakdown of academic impact, for papers by Amaury Daste Breakdown of academic impact, for papers by Zhuoran Yao Breakdown of academic impact, for papers by Guoqiang Wang Breakdown of academic impact, for papers by Zhefeng Liu Breakdown of academic impact, for papers by Audrey Simonaggio Breakdown of academic impact, for papers by Aliyah Pabani Breakdown of academic impact, for papers by Giulia Mazzaschi Breakdown of academic impact, for papers by Jia Song
Rankless by CCL
2026